Analyst consensus rating
PDS Biotechnology Analyst Rating: Strong Buy
PDSB is rated Strong Buy by 2 analysts with a $5.75 target. As of 2026-08-28.
Direct answer
PDS Biotechnology's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.75.
Forecast evidence checked August 28, 2026.
Get free PDS Biotechnology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.22
- Average price target
- $5.75
- High price target
- $7.00
- Low price target
- $4.50
- Low target gap
- +1,965.2%
- Target upside
- +2,538.8%
- High target gap
- +3,112.5%
- Target range width
- 1,147.3%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- August 28, 2026
- Valid through
- September 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for PDS Biotechnology?
PDS Biotechnology has a verified Strong Buy consensus. The same dataset has an average price target of $5.75.
How far are PDS Biotechnology's low and high targets from the recorded price?
The low target implies +1,965.2%, while the high target implies +3,112.5%.
How many analysts are included in PDS Biotechnology's consensus?
The verified consensus includes 2 analysts.
How is PDS Biotechnology's target upside or downside calculated?
The average target of $5.75 is divided by the recorded price of $0.22, then one is subtracted to produce +2,538.8%. This does not guarantee a future return.
When was PDS Biotechnology's analyst forecast verified?
The data was verified on 2026-08-28. The dataset is valid through 2026-09-04.